NKGen Biotech Files 8-K: Material Agreement & Exhibits
| Field | Detail |
|---|---|
| Company | Nkgen Biotech, Inc. |
| Form Type | 8-K |
| Filed Date | Sep 29, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $11.50 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, exhibits, corporate-name-change
Related Tickers: NKGN
TL;DR
NKGen Biotech filed an 8-K on 9/25/25 for a material agreement and exhibits.
AI Summary
On September 25, 2025, NKGen Biotech, Inc. filed an 8-K report. The filing indicates the company entered into a material definitive agreement and also includes financial statements and exhibits. NKGen Biotech, Inc. was formerly known as Graf Acquisition Corp. IV.
Why It Matters
This filing signals a significant business development for NKGen Biotech, Inc., potentially involving new contracts or financial arrangements that could impact its operations and future growth.
Risk Assessment
Risk Level: medium — Material definitive agreements and the filing of financial statements can introduce new risks or opportunities that are not yet fully understood.
Key Players & Entities
- NKGen Biotech, Inc. (company) — Registrant
- September 25, 2025 (date) — Date of earliest event reported
- Graf Acquisition Corp. IV (company) — Former company name
FAQ
What is the nature of the material definitive agreement entered into by NKGen Biotech, Inc. on September 25, 2025?
The filing does not specify the details of the material definitive agreement, only that one was entered into.
What specific financial statements and exhibits are included in this 8-K filing?
The filing indicates that financial statements and exhibits are included, but does not list their specific contents.
When did NKGen Biotech, Inc. change its name from Graf Acquisition Corp. IV?
The date of the name change from Graf Acquisition Corp. IV to NKGen Biotech, Inc. was February 10, 2021.
What is NKGen Biotech, Inc.'s Standard Industrial Classification (SIC) code?
NKGen Biotech, Inc.'s SIC code is 2836, for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Where is NKGen Biotech, Inc. headquartered?
NKGen Biotech, Inc. is headquartered at 3001 Daimler Street, Santa Ana, CA, 92705.
Filing Stats: 601 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-09-29 16:05:45
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share NKGN OTC Expert
- $11.50 — of Common Stock at an exercise price of $11.50 per share NKGNW OTC Expert Market
Filing Documents
- ea0259029-8k_nkgen.htm (8-K) — 28KB
- ea025902901ex10-1_nkgen.htm (EX-10.1) — 31KB
- 0001213900-25-093062.txt ( ) — 275KB
- nkgn-20250925.xsd (EX-101.SCH) — 4KB
- nkgn-20250925_def.xml (EX-101.DEF) — 26KB
- nkgn-20250925_lab.xml (EX-101.LAB) — 36KB
- nkgn-20250925_pre.xml (EX-101.PRE) — 25KB
- ea0259029-8k_nkgen_htm.xml (XML) — 5KB
01. Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement. On September 25, 2025, NKGen Biotech, Inc. (the " Company ") and Yong Man Kim entered into a consulting agreement, dated as of September 10, 2025, (the " Agreement ") pursuant to which Dr. Kim will continue to serve as the Company's Chief Scientific Officer in a consulting capacity. Dr. Kim transitioned from his previous role as an employee of the Company to an independent contractor. This change accommodates Dr. Kim's recent appointment as President of NKMax while enabling him to continue contributing to the Company's scientific leadership and strategy. The Company is pleased to retain Dr. Kim's deep expertise and ongoing involvement in advancing its research and development efforts. The term of the Agreement is indefinite, and it may be terminated by either party at will. The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 10.1 Consulting Agreement, by and between NKGen Biotech, Inc. and Youngman Kim, dated September 25, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NKGEN BIOTECH, INC. Date: September 29, 2025 /s/ Paul Y. Song Name: Paul Y. Song Title: Chief Executive Officer (Principal Executive Officer) 2